Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study.

Stefan SchneiderGary BlickChristina BurkeDouglas WardPaul BensonFranco FelizartaDallas GreenCynthia DonovanGavin HarperDeanna MerrillAimee A MetznerKatie MycockHannah WallisJimena PatarroyoAndrew P BroganAlan K Oglesby

Published in: Infectious diseases and therapy (2024)

Motivation for selecting DTG-based 2DRs was primarily driven by a desire to avoid or manage toxicities and simplify treatment. Results demonstrate that DTG/3TC and DTG/RPV are effective in real-world settings, with few discontinuations, reflecting data from clinical trials.

Keyphrases

hiv infected patients
clinical trial
antiretroviral therapy
big data
emergency department
open label
drug induced
replacement therapy
study protocol
phase iii